Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.GeoVax Labs has reported successful early results from two ongoing AIDS prevention phase I human vaccine trials.
Subscribe to our email newsletter
Results from the first low dose trial indicate a good safety profile as well as positive immune responses in human volunteers receiving 1/10th dose of GeoVax's AIDS vaccine. Results from a second larger full dose trial also indicate a good safety profile in participants.
The GeoVax vaccines being tested are designed to prevent the development of AIDS by vaccinating individuals prior to infection with the virus. These vaccines contain the three major genes of the HIV-1/AIDS virus and mimic actual virus infections by producing non-infectious HIV-like particles in vaccinated individuals.
Based on the excellent safety demonstrated in the 1/10th dose vaccine trial, a full dose human trial started in September 2006. The immune response generated in the majority of volunteers receiving 1/10th dose of GeoVax's vaccines suggests that the vaccines, when administered at full dose, may elicit outstanding responses.
GeoVax commented that the data supports the accelerated planning for a large phase II human trial across North and South America and the Caribbean with an earlier start date than originally anticipated.
GeoVax said more information will be released on the full dose trial when available later in 2007.